Table 1 Characteristics of included studies
NO. | Author | Pentoxifylline group | Control group | Jada scores | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Number | Gestational age (weeks) | Male (n) | Birth weight (g) | Methods | Number | Gestational age (weeks) | Male (n) | Birth weight (g) | Methods | |||
1 | Shabaan 2015 [21] | 60 | 30.2 ± 2.5 | 34 | 1404 ± 417 | intravenous pentoxifylline 5 mg/kg/hr. for 6 h on 6 successive days | 60 | 30.1 ± 2.2 | 44 | 1370 ± 471 | matched placebo | 5 |
2 | Akdag 2014 [22] | 51 | 31 (24–42) | 29 | 1490 (620–4580) | pentoxifylline 6 mg/kg/h intravenously, over 4 h, daily for three consecutive days | 51 | 31 (25–40) | 33 | 1410 (620–4300) | matched placebo | 4 |
3 | Adel 2010 [23] | 17 | 35.94 ± 4.04 | 9 | 2470 ± 890 | pentoxifylline 5 mg/kg/h for 6 h, for 6 successive days | 20 | 36.05 ± 3.2 | 11 | 2210 ± 590 | matched placebo | 4 |
4 | Ali 2006 [24] | 25 | 32–37 | – | 950–2580 | pentoxifylline 5 mg/kg/h for 6 h, for 3 successive days | 25 | 32–37 | – | 1000–2650 | matched placebo | 3 |
5 | Selim 2004 [29] | 13 | 37.62 ± 2.43 | – | 2509 ± 549 | initiately 0.5 h before beginning antibiotic therapy and given in a dose of 0.5 mg/kg/h by continuous infusion for 24 h | 7 | 38 ± 2.08 | – | 2822 ± 637 | matched placebo | |
6 | Lauterbach 1999 [30] | 40 | 31.6 ± 2.9 | 23 | 1690.2 ± 396.5 | pentoxifylline 5 mg/kg/h for 6 h, for 6 successive days | 38 | 32.8 ± 3.01 | 20 | 1749.8 ± 475.6 | matched placebo | |
7 | Lauterbach 1996 [20] | 16 | 31.54 ± 31 | – | 1752.09 ± 483.4 | pentoxifylline 5 mg/kg/h for 6 h, for 3 successive days | 16 | 32.35 ± 33 | – | 1861.29 ± 511.7 | matched placebo | |